



Ryokichi Mochida



Nobuo Mochida



Ei Mochida

- 1913 Mochida was established by Ryokichi Mochida, and started production and marketing of *Luestin* (antiluetic) and *Ogoko* (ophthalmic ointment).
- 1918 The Company was renamed Mochida Pharmaceutical Company.
- 1930 *Pelanin* (first estrogen preparation developed in Japan)
- 1945 The Company was incorporated.
- 1951 *Sprase* (first hyaluronidase preparation developed in Japan)
- 1954 Began overseas marketing with exports to Taiwan.
- 1956 *Thrombin Mochida* (hemostatic enzyme)
- 1959 Transferred focus of sales strategy to obstetrics and gynecology.
- 1962 Established the Immunology Division.
- 1963 Listed on the Second Section of the Tokyo Stock Exchange (TSE).
- 1964 Nobuo Mochida was appointed president.  
*Gonavis* (Japan's first immunological pregnancy test kit); *Kimotab* (anti-inflammatory)
- 1967 Completed the Research Laboratory in Oji.
- 1970 Established the Paramedical Division.  
*Gonavislide* (pregnancy test kit); *Uronase* (fibrinolytic); *Skina Babe* (baby bath oil)
- 1972 Established the Medical Electronics and Equipment Division.  
Completed the Shizuoka Plant.
- 1975 Listed on the First Section of the TSE.
- 1976 Completed the new headquarters office building in Yotsuya.
- 1978 Received a Noteworthy Invention Testimonial from the Science and Technology Agency for the *Medilaser balance-type surgical laser head*.
- 1979 *Rocornal*
- 1980 Developed monoclonal antibody technology for an immunodiagnostic test.  
*Medilaser-S*
- 1981 Signed an agreement with Hayashibara Biochemical Laboratory, Inc. for joint research of interferon.
- 1982 Completed the Fuji Central Research Laboratory.
- 1983 Established the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
- 1984 Nobuo Mochida was awarded the Medal with Purple Ribbon for research on the first surgical laser unit developed in Japan.  
*Arasena-A*
- 1985 Ei Mochida was appointed president.  
*Miraclid*
- 1986 *Florid®-F injection*; *Grandaxin*
- 1987 Ei Mochida was awarded the Medal with Purple Ribbon for R&D activities on an immunochemical diagnostic reagent.
- 1988 Signed an agreement with Taisho Pharmaceutical Co., Ltd., allowing that company to market *Dermarin*, an OTC drug for treating dermatomycosis.  
*Collage Soap series*; *Isoprinosine®*; *IFNB Mochida*
- 1989 Finalized agreements with Upjohn Co. for developing and marketing its prostaglandin derivative.  
*Tecipul*
- 1990 Susumu Watanabe was appointed president.  
Concluded a marketing agreement with Matsushita Electric Industrial Co., Ltd. for the *Medilaser-10S* fiber-optic carbon dioxide surgical laser unit.  
*Epadel Capsule 300*
- 1991 Commenced operations at the Otawara Plant.  
Concluded agreement of an antimycotic agent with Imperial Chemical Industries, PLC.  
*Mammotec*

- 1992 Signed agreements with Ostex International, Inc. for the commercialization and marketing of *Osteomark*<sup>®</sup>; and with Yokogawa-Hewlett-Packard, Ltd. to market an obstetric care unit. *Arasena-A Ointment*; *Thrombin Oral Fine Granules*; *Bathquina*  
Commenced J-MIC (EBM study for *Rocorna*).
- 1993 *Florid*<sup>®</sup> Oral Gel; *Sonotec-IV*; *Collage Liquid Soap*
- 1994 Additional indication for *Epadel* (for hyperlipidemia) was approved.  
*Miraclid liquid formulation for injection*
- 1995 Signed agreements with Smithkline Beecham Seiyaku K.K. for the co-marketing of *Arasena-A*.
- 1996 Signed agreements with Norian Corporation for the development and marketing in Japan of *Norian SRS*<sup>®</sup>; and with Daiinippon Pharmaceutical Co., Ltd. for the co-marketing of *Epadel* in Japan.  
Commenced JELIS (EBM study for *Epadel*).
- 1997 Concluded distribution agreement with Ajinomoto Co., Inc. for *Atelec*<sup>®</sup>.  
*Atelec*<sup>®</sup>; *Gonastick*
- 1998 Co-marketed Daiinippon Pharmaceutical's *Cetapril*<sup>®</sup> (ACE inhibitor).  
*Osteomark*<sup>®</sup>; *Amtec*
- 1999 Naoyuki Mochida was appointed president.  
Additional indications for *IFNβ* (for CML) and *IFNβ* (for SSPE) approved; concluded distribution agreement with Janssen Kyowa Co., Ltd. for *Ortho*<sup>®</sup> 777-28/M-21; licensed a patent of Fas/ FasL (for gene therapy) to Novartis.  
Licensed a patent of Fas/FasL (for screening) to Bristol Myers Squibb.  
*Epadel S 300 and 600*; *Collage Furfur*; *Miotecter*<sup>®</sup>
- 2000 Signed agreements with RIKEN for co-research in structural genomics.
- 2001 Signed agreements with 3M for the development and marketing of *Aldara*.  
*Arasena-A 3% cream*; *Gonastick25*; *Collage Essence*
- 2002 Signed agreements with Aventis Pharma Ltd. for the distribution and co-promotion of *Suprecur*<sup>®</sup>; and with Lundbeck A/S for the co-development and co-marketing of escitalopram. Established the nutraceutical business.  
Obtained ISO 14001 certification for the Otawara Plant.  
*Suprecur*<sup>®</sup>
- 2003 Signed agreements with Novo Nordisk for the distribution of *Novo-Heparin*; and with Medix Biochemica Oy and Unitika Ltd. for the distribution of a diagnostic test kit for acute pancreatitis.  
Started operation of Mochida Medical Systems Co., Ltd.  
*Thrombin Mochida Soft bottle*; *Novo-Heparin*; *Collage S series*
- 2004 Started operation of Mochida Healthcare Co., Ltd.  
Started operation of Mochida Siemens Medical Systems Co., Ltd.  
*Epadel S 900*
- 2005 Started operation of Mochida Pharmaceutical Plant Co., Ltd.
- 2006 *Collage Furfur Liquid Soap*; *Collage Furfur S*
- 2007 Signed agreements with JCR Pharmaceuticals Co., Ltd. for co-development and commercialization of a cellular-based drug; with Novartis Pharma K.K. for co-promotion of *Diovan*<sup>®</sup> (agreement terminated end of 2008); and with United Therapeutics Corporation for the distribution of *Remodulin*<sup>®</sup>.  
*Beselna Cream 5%*
- 2008 Signed a license agreement with Wyeth Pharmaceuticals Inc. for TRPV1 receptor antagonists (agreement terminated 2010).  
*Dinagest*; *Divigel*; *Collage White Peel*
- 2009 Signed a license agreement with Shire Pharmaceuticals Group plc (U.K.) for *LIALDA*<sup>®</sup>.  
*Gonastick W*, *Collage Furfur Next*
- 2010 Signed agreement with Fuji Pharma Co., Ltd. for co-development of G-CSF; and with Mitsubishi Tanabe Pharma Corporation for co-marketing of *Escitalopram*.



Susumu Watanabe



Naoyuki Mochida

